Immuneering's Atebimetinib Shows 17.3-Month Survival in Pancreatic Cancer Trial
Event summary
- Immuneering's Phase 2a trial of atebimetinib + chemotherapy in first-line pancreatic cancer patients showed 17.3-month median overall survival vs. 8.5 months for standard care.
- 84% of participants maintained or gained weight at three months, indicating favorable tolerability.
- Global Phase 3 MAPKeeper 301 trial (NCT07562152) is actively recruiting, with first patient dosing expected in mid-2026.
- Data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
The big picture
Immuneering's data positions atebimetinib as a potential paradigm shift in first-line pancreatic cancer treatment, where survival gains have been incremental. The favorable tolerability profile could differentiate it from intensive chemotherapy regimens. The Phase 3 trial's success will determine whether this approach becomes a new standard of care.
What we're watching
- Clinical Validation
- Whether the Phase 2a results will translate into successful Phase 3 outcomes and regulatory approval.
- Competitive Positioning
- How Immuneering's survival data compares to emerging pancreatic cancer therapies in development.
- Combination Strategies
- The pace at which Immuneering advances atebimetinib + anti-PD-1 combinations into later-stage trials.
Related topics